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appeared in the circulation 4 h after labeling with BrdU and peaked at 18 h when 34.3 Ϯ 5.8% of monocytes were labeled. The calculated transit time of monocytes through bone marrow was 38.1 Ϯ 3.1 h in control rabbits with a half-life (T 1/2) of 12.7 h. Instillation of Streptococcus pneumoniae into the lung accelerated the release of monocytes from bone marrow (peak at 10 h) and shortened their bone marrow transit time (27.1 Ϯ 1.8 vs. 22.6 Ϯ 0.6, vehicle vs. pneumonia; P Ͻ 0.05). We conclude that this nonradioisotope method provides a novel way to monitor monocyte kinetics and confirmed previous reports that a focal pneumonia shortens monocyte marrow transit and increases their release into the circulation.
leukocytes; transit time; half life; pneumonia; rabbits THE RECRUITMENT OF LEUKOCYTES into lung tissues with acute lung inflammation is characterized by an early recruitment of polymorphonuclear leukocytes (PMN) (1-2 h), followed by monocytes that initially accumulate in small numbers compared with the PMN but become the predominant cell within 24-48 h (2, 6, 8, 10, 42) . This sequential recruitment of leukocytes at the sites of inflammation is one of the fundamental paradigms in the innate immune response (8) and is a key element for effective host defense against microorganisms and foreign material deposited in the lung. Monocytes recruited into the air spaces differentiate into macrophages that play a pivotal role in clearing microorganisms and particles from the lung and in initiating and regulating the host response. The phagocytosis and processing of particles by the macrophages is associated with the production of important inflammatory mediators that act systemically to initiate the acute phase reaction, recruit other leukocytes to the site of inflammation, and stimulate the adaptive immune system (37, 39) . They also assist in triggering the termination and resolution of the inflammatory response in the lung.
Monocytes recruited into the lung originate from either the intravascular pool of monocytes (21) or from precursors in the marrow (38) . In the marrow, the monocytes originate from stem cells that undergo three divisions (monoblast, promonocyte, and monocyte) before their release into the circulation. Within the vascular space, the monocytes reside in a marginated pool that can be twice as large as the number in the monocytes that are circulating in the blood (37) . The circulating half life of monocytes is ϳ71 h in humans (43) , ϳ42 h in rats (41) , and 17.4 h in mice (37) . In the tissues, monocytes differentiate into tissue macrophages that have a life span estimated to be 2-5 wk (39) . The increase in tissue macrophages at the site of infection is accompanied by an increase in monocytes in the circulating blood (37, 38) , and the majority of the tissue macrophages are derived from this circulating pool of monocytes. These kinetic studies have all been performed using radioisotopes (14, (37) (38) (39) 41) .
Inflammatory mediators released from the inflamed lung have the ability to induce the marrow to release monocytes and stimulate monocytopoiesis. The hematopoietic growth factors, granulocyte/macrophage colony-stimulating factor (GM-CSF) and M-CSF, interleukin-6 (IL-6), and the ␤-chemokines are thought to be important mediators for the production and mobilization of monocytes from the bone marrow (22, 25) . Lung cells such as alveolar macrophages and epithelial cells are a major source for these mediators when they process microorganisms and inhaled ambient particles (2, 9, 16, 32, 35) .
This study was designed to develop a nonisotopic method to quantify the release of monocytes from the bone marrow, measure their half-life in the circulation, and calculate their transit through the bone marrow in rabbits. The thymidine analog 5Ј-bromo-2Ј-deoxyuridine (BrdU) was used to label dividing monocytes in the bone marrow and follow their release into the circulation. The monocytes that were labeled with BrdU in the marrow were specifically identified as monocytes in the peripheral blood using the monoclonal antibody RbM2 that is specific for rabbit monocyte lysosomal antigen (23, 26, 44) . The kinetics of these cells was examined both in the normal control state and in a well-established model of pneumococcal pneumonia in rabbits (33) .
MATERIALS AND METHODS

Experimental Animals
Female New Zealand White rabbits (n ϭ 28; weight, 2.4 Ϯ 0.3 kg) were used in this study, and the protocol was approved by the Animal Experimentation Committee of the University of British Columbia.
Experimental Design
Release of BrdU-labeled monocytes from bone marrow. The time from BrdU incorporation into dividing monocyte precursors in the marrow until their appearance in the circulation was determined by infusing BrdU (100 mg/kg; Sigma Chemical, St. Louis, MO) at a concentration of 10 mg/ml in sterile saline into the marginal ear vein over a period of 15 min. Blood samples were obtained from the central ear artery just before (baseline) and at intervals from 2 to 72 h after BrdU infusion was used to measure total leukocyte counts and determine the number of BrdU-labeled monocytes (MO BrdU ). Sedation [Fentanyl (20 g/kg) and droperidol (1 mg/kg)] was administered by subcutaneous injection to facilitate blood collection.
Clearance of MO BrdU from the circulation. To determine the clearance of monocytes from the circulation, whole blood containing labeled monocytes was transfused from donor rabbits to serum compatible recipients. In a preliminary study, donor rabbits (n ϭ 3) were given BrdU at a dose of 100 mg/kg every 2 h for a total of 5 injections, and blood was obtained from the central ear artery of these rabbits before and at 4, 8, 18, 21, 24, 27, 30 , and 48 h after the first BrdU injection to determine the time of maximum number of monocytes were labeled with BrdU. On the basis of this result, the BrdU-labeled monocytes were harvested from another three donor rabbits and transfused to six recipients as 15 ml/kg of whole blood by a method previously described in detail (3, 20) . The donor-recipient pair was chosen by their serum compatibility that was confirmed by microscopic evidence of hemolysis and agglutination after the recipient serum and donor red cells were combined. Leukocyte-rich plasma (LRP) made from the donor rabbit blood was incubated with recipient serum in microwells where trypan blue uptake was used to determine cytotoxicity using recipient LRP and recipient serum as a control (29 BrdUinfused represents the number (ϫ10 6 /ml) of MO BrdU infused (monocyte count/ml ϫ ml of fluid infused ϫ fractionMO BrdU ). Effect of pneumonia on monocyte transit time through the marrow. Rabbits (n ϭ 6) were anesthetized with ketamine hydrochloride (80 to 100 mg/kg, intramuscularly) and xylazine (10 to 15 mg/kg, intramuscularly) and challenged with intrabronchial instillation of either Streptococcus pneumoniae (1.5 ϫ 10 9 organisms mixed with 1 ml of saline and colloidal carbon) or vehicle (1 ml of saline mixed with colloidal carbon to mark the area of instillation for histological sampling) as a control 4 h after treatment with BrdU. This time point was selected for instillation because first MO BrdU appeared in the circulation 4 h after BrdU administration. Briefly, streptococci or vehicle was instilled into the lower lobe of the lung by inserting a pediatric feeding tube through the tracheal rings and positioned via fluoroscopy as previously described in detail (17, 33) . The animal was then allowed to recover, and the peripheral blood samples were taken just before (baseline) and at intervals from 4 to 168 h after BrdU injection and analyzed for the presence of MO BrdU in the circulation as described below.
Leukocyte Counts
One milliliter of blood was collected in standard Vacutainer tubes containing EDTA (Becton Dikinson, Rutherford, NJ), and WBC counts were determined on a model SS80 Coulter counter (Coulter Electronics, Hilaeh, FL). Differential WBC counts were done by counting 200 leukocytes in randomly selected fields of view on Wright-Giemsa stained blood smears.
Immunohistochemical Detection of BrdU-labeled Leukocytes in the Circulation
Sample preparation. Blood collected in acid-citrate-dextrose (ACD) was used to obtain LRP. Erythrocytes in the ACD blood sample were sedimented for 25-30 min by the addition of an equal volume of 4% dextran (average molecular weight, 162,000; Sigma) in polymorphonuclear leukocytes (PMN) buffer (in mmol/l: 138 NaCl, 27 KCl, 8.1 Na 2HPO4 7H2O, 1.5 KH2PO4, and 5.5 glucose, pH 7.4). The resulting LRP was cytospun onto slides precoated with 3-aminopropyltri-ethoxysilane by cytocentrifugation at 1,200 revolutions/ min with a Cytospin 2 (Shandon Scientific, Runcorn, UK) for 4 min. The cytospun specimens were air-dried and fixed in acetone for 10 min.
Double immunoenzymatic staining of monocytes for RbM2 and BrdU. Monocytes were identified using RbM2 (ICN Biomedicals, Aurora, OH), a monoclonal antibody specific for rabbit monocyte lysosomal antigen (23, 26, 44) . Cells on cytospins were stained for the presence of both monocyte cytoplasm RbM2 antigen (red) and nuclear BrdU (blue) using the alkaline phosphatase and anti-alkaline phosphatase (APAAP) method (5) and a modified double immunolabeling technique previously described (19, 34) . Briefly, cells on the cytospin were incubated with 6 mg/ml of N-octyl ␤-D-glucopyranoside (Sigma) as a permeabilizer for 7 min and then with 5% rabbit serum for 15 min before application of 5 g/ml of RbM2 for 90 min in a humidity chamber at room temperature. As a negative control, nonspecific mouse immunoglobulin G1 (IgG1) at 5 g/ml was used. A 1:20 dilution of rabbit anti-mouse IgG (DAKO Laboratories, Copenhagen, Denmark) was applied and followed by the anti-mouse IgG alkaline phosphatase-conjugated complex (DAKO) in a 1:50 dilution for 20 min, respectively. This procedure was repeated in the same concentration for 15 min. All antibodies were prepared in 50 mmol/l Tris ⅐ HCl and 150 mmol/l NaCl, pH 7.6 (TBS), with 1% bovine serum albumin, and slides were washed in TBS twice for 10 min between each antibody application. The alkaline phosphatase was developed for 20 min in 50 ml of TBS at pH 8.7 after the addition of a mixture of 0.5 ml of 4% sodium nitrite, 0.2 ml of 5% fuschin (Merck, Rahway, NJ) in 2 mol/l HCl, and 50 mg naphthol AS-B1 phosphate (Sigma) dissolved in 0.3 ml of N,N-dimethylformamide. Endogenous alkaline phosphatase was blocked by the addition of 17.5 mg of levamisole (Sigma). Specimens were then fixed with 1% paraformaldehyde for 15 min before being stained for the presence of nuclear BrdU using a second APAAP procedure as described in detail previously (3, 19, 34) . The alkaline phosphatase was developed with a commercially available kit, HistoMark Blue (Kirkegaard and Perry, Gaithersburg, MD), for 10 min in the dark. Slides were washed with tap water, mounted in an aqueous medium (Gelvatol), and evaluated on a Zeiss Universal Research light microscope (Model 2R; Zeiss, Oberkochen, Germany) at ϫ400 magnification.
Evaluation of MO BrdU . Monocytes with both cytoplasmic stain (red), and nuclear stain (blue) were counted as BrdUlabeled (MO BrdU ). Cytospin slides were coded and evaluated by investigators without knowledge of their origin. MO BrdU were evaluated on the light microscope in random field of view by counting 200 monocytes per slide. Results are expressed as the percentage of monocytes or the number per milliliter of blood that is BrdU-labeled.
Calculation of the Half-Life of Monocytes
The exponential decrease of the number of MO BrdU in the circulation is described by the equation Nt ϭ number of MO BrdU in the circulation at time t; and NTmax ϭ number of MO BrdU in the circulation at time Tmax. Because the half-life (T1/2) can be estimated as the time at which Nt is NTmax ϫ 1/2, the late-decay equation for T1/2 becomes T1/2 ϭ ln 2/k. The constant k was calculated with the random-effects regression method (7). The confidence interval (4) was obtained by deriving the lower and upper bounds of the 95% confidence interval for the slope, k.
Transit Time of MO BrdU through the Bone Marrow
The transit time on monocytes through the bone marrow was calculated from the appearance of BrdU-labeled cells in the circulation over time and corrected for the disappearance (T 1/2) of the cells in the circulation (33) 
Statistical Analysis
All values are expressed as means Ϯ SE. Data were analyzed using a repeated measure analysis of variance (ANOVA) over time, and the effect of multiple comparisons was corrected using the Bonferroni method. Transit time was compared by one-way ANOVA, followed by Fisher's protected least significant difference test as the post hoc test among the groups. Comparisons of transit time or half life between monocytes and PMN were made by Student's t-test. A corrected P Ͻ 0.05 was considered significant throughout the study. Figure 1 shows double immunolabeling of monocytes for both cytoplasm RbM2 (red) and nuclear BrdU (blue). All RbM2-positive cells (monocytes) were classified as either BrdU positive or negative. The influence of the double-labeling procedure on the presence of cytoplasm RbM2 and nuclear BrdU expression was evaluated by comparing the number of positive mono- Fig. 1 . Photomicrograph of double immunolabeling of circulating monocytes for cytoplasm RbM2 (red) and nuclear 5Ј-bromo-2Ј-deoxyuridine (BrdU) (blue). Monocytes were detected as cells with cytoplasm red stain, and the monocytes with any nuclear blue stain were counted as BrdU-labeled cells on the microscope at ϫ400 magnification. Bar represents 10 m.
RESULTS
Double Immunolabeling of Monocytes
cytes of all nucleated cells for each antigen with paired slides stained for a single antigen in 10 randomly selected sides. There was no difference in the number between single-or double-stained cells.
Clearance of MO
BrdU from the Circulation Figure 2 shows the appearance of labeled monocytes in the circulation of donors after BrdU injection at a dose of 100 mg/kg every 2 h for 5 injections. The number increased gradually, and ϳ80% of the circulating monocytes were labeled 24 h after the initial injection of BrdU. After the transfusion of donor whole blood containing 83 Ϯ 2.0% of labeled monocytes, the number of MO BrdU in the circulation of the recipients fluctuated to a peak at 1 h, rapidly decreased over the next 6 h, and then relatively slowly declined over the next 48 h (Figure 3) . The time required to achieve the maximal number of MO BrdU in the circulating blood of the recipients (T max ) was 1 h and was applied to the rate decay equation to calculate the T 1/2 of monocytes in the circulation. The calculated T 1/2 of MO BrdU in the circulation using this method was 12.7 h with a 95% confidence interval of 10.7-15.6 h, which is significantly longer the 4.5 h with 95% confidence interval of 4.1-4.9 h reported for PMN in rabbits using the same technique (3). Figure 4 shows the appearance of MO BrdU in the circulation after pulse labeling with 100 mg/kg BrdU. The first MO BrdU appears in the circulation 4 h after labeling, followed by a rapid increase in the percentage of MO BrdU to reach a peak at 18 h (34.3 Ϯ 5.8% of circulating monocytes labeled), and then a slow decline over the next 72 h (at 24 h: 21.0 Ϯ 2.3%, at 48 h: 12.7 Ϯ 2.7%, at 72 h: 8.7 Ϯ 2.0%). The absolute number of circulating monocytes was stable during the study period. The calculated mean transit time of MO BrdU through the bone marrow in control rabbits was 38.1 Ϯ 3.1 h, which was much shorter than the values for PMN (95.6 Ϯ 3.6 h) (P Ͻ 0.001) previously reported from our laboratory using a similar technique (33) . Figure 5 shows the percentage of BrdU-labeled monocytes in the circulation in rabbits with and without a focal pneumococcal pneumonia. No change was seen in monocytes or PMN counts in the circulation during the study period (data not shown) with a significant increase in band cell counts at 16 h after instillation of pneumococci (1.34 Ϯ 0.35 ϫ10 9 /l vs. 0.59 Ϯ 0.16 ϫ10 9 /l, S. pneumoniae-challenged vs. con- Fig. 3 . Changes in a fraction of circulating BrdU-labeled monocytes infused into recipient rabbits (n ϭ 6) as whole blood. BrdU-labeled monocytes in circulating blood of recipients reach a steady state at 1 h and then disappear from the circulation over the next 48 h. Each data point represents means Ϯ SE. 8 /l; circulating monocytes, 0.79 Ϯ 0.18 ϫ10 9 /l) after BrdU labeling, followed by a rapid increase to reach a peak at 18 h (number of MO BrdU , 2.14 Ϯ 0.68 ϫ10 8 /l; circulating monocytes, 0.60 Ϯ 0.10 ϫ10 9 /l) and then slow decline. Each value represents means Ϯ SE from 3 or 6 rabbits (n ϭ 6 at 0, 8, 16, 24, 48, and 72 h).
Transit Time of Monocytes through the Bone Marrow
Behavior of MO BrdU through the Marrow into the Circulation during Pneumonia
trol; P Ͻ 0.05). The fraction of MO BrdU rapidly increased after the instillation to peak at 10 h (S. pneumoniae-challenged) and 12 h (control) with a more rapid clearance of MO BrdU from the circulation in the S. pneumoniae-challenged group (24-48 h; P Ͻ 0.05). The transit time of MO BrdU through the marrow was significantly shorter in the S. pneumoniae-challenged group compared with vehicle instillation (22.6 Ϯ 0.6 vs. 27.3 Ϯ 1.8 h; P Ͻ 0.05) or S. pneumoniae-challenged group compared with no instillation (22.6 Ϯ 0.6 vs. 38.1 Ϯ 3.1 h; P Ͻ 0.01) ( Table 1) .
DISCUSSION
Labeling leukocytes with radioisotopes ex vivo to study their behavior and turn over rates has been previously described (14, 38, 39, 41) , but these procedures have the disadvantage of cell activation during the purification and labeling procedures (3, 13, 37) . Our laboratory has developed an alternative method for the study of PMN that labels the cells in vivo without the use of isotopes that allows the labeled cells to be delivered in whole blood to experimental animals without manipulating them in vitro (3, 20) . In the present study, we took advantage of the availability of a monoclonal antibody that specifically identifies monocytes to apply this technique to the study of monocyte kinetics. Rapidly dividing cells were labeled in vivo by delivering multiple doses of the thymidine analog, BrdU, to donor rabbits and transferring the labeled cells to the experimental animals in whole blood without manipulation. The kinetics of the disappearance of labeled monocytes from the blood was determined on cytospins of LRP prepared from peripheral blood samples using a monoclonal antibody specific for monocytes (RbM2 directed against monocyte lysosomal antigen) to positively identify BrdU-labeled cells that were monocytes (Fig. 1) . These values were used to calculate the T 1/2 of disappearance of the BrdUlabeled monocytes, and we applied this value in separate experiments to determine the transit time of the BrdU-labeled monocytes through the bone marrow. In these experiments, a single injection of BrdU was used to label the monocytes in the marrow and measure their transit time through the marrow pools from their rise and fall in the peripheral blood corrected for their rate of disappearance from the circulation. The results show that monocyte transit through the marrow is considerably shorter than PMN transit and that monocytes spend a longer time in the circulation than PMN. They also show that a focal pneumonia significantly shortens monocyte transit time through the bone marrow and accelerates their release into the circulation.
Monocyte turnover and behavior have been studied in human (14, 39) , mouse (37, 38) , and rat (41) using radiolabeled purified monocytes or pulse labeled of dividing cells with [ The purification of monocytes is difficult and time consuming, and labeling with radioisotopes also requires decontamination and disposal of radioactive waste. The ability to label the dividing cells in vivo and transfer them to recipient animals in whole blood avoids all of these difficulties. However, transfusing blood cells or blood products between outbred animals could potentially cause histocompatibility reactions. In this study, we performed serum cross-match between donors and recipients for red cell (agglutination microscopically) and leukocyte [cytotoxicity test (29) ] compatibility. This method does not exclude all possible histocompatibility reactions, but several studies from our laboratory using this transfusion method have shown no measurable immune reaction either clinically (fever, diarrhea, lost of appetite, convulsion, or death) or in blood cell counts, marrow stimulation, and leukocyte activation (3, 19, 20) . Although we cannot exclude mild activation of leukocytes, histocompatibility reactions are unlikely to be a significantly confounding factor using this method of transfusing labeled leukocytes.
Our preliminary experiments showed that the short transit time of monocytes through the marrow required that the donors receive 5 injections of BrdU over 8 h to get ϳ85% of the monocytes in the peripheral blood labeled at 24 h (Fig. 2) . Transfer of these labeled cells in whole blood from the donor animals to serumcompatible recipients showed that the calculated T 1/2 All values are means Ϯ SE; n ϭ no. of experiments. of the BrdU-labeled monocytes in the circulation was 12.7 h (95% confidence interval of 10.7 and 15.6 h). This value is shorter than the previously reported values of ϳ24 h measured using 51 Cr-or 111 In-labeled monocytes in rabbits and calculating T 1/2 over shorter periods in rabbits (6, 10, 21) . It is also longer than T 1/2 of PMN in the circulation of rabbits measured using the same technique (3). After transfusion of labeled whole blood, the percentage of BrdU-labeled monocytes remaining in the circulating pool at steady state (1 h) was 41% (Fig. 3) , suggesting that the remaining 59% of the monocytes had moved to the marginated intravascular pool. These results are consistent with the studies in mice (37, 40) and humans (15) where the marginated pool has been estimated to be ϳ60 and ϳ75%, respectively. In contrast, using indium-labeled monocytes in rabbits, Ohgami and colleagues (21) showed that ϳ85% of monocytes had shifted from the circulating to the marginated pool at 1 h in rabbits and that the majority of the marginated cells were in the liver and lung. Because of minimal cell manipulation with this whole blood method in contrast to purification and isotope labeling, we suspect that the present results more closely represent the behavior of monocytes in vivo.
In the experiments where a single dose of BrdU was given to pulse label the dividing monocytes in the marrow, the first BrdU-labeled monocytes appeared in the circulation 4 h after the BrdU injection (Fig. 4) . This represents the minimum time from DNA synthesis of the last division in the marrow until release of the monocytes into the circulation. This rapid release of monocytes after labeling suggests that monocytes translocate from the marrow to the peripheral blood soon after their last division and do not mature in the marrow. This contrasts with PMN that have a distinct maturation pool in the marrow where they reside before their release into the circulation (1, 33) . The rapid release of monocytes from the marrow and their long T 1/2 in the circulation suggest that they mature in the circulation before they migrate into the tissues.
Assuming that all mitotic cells in the bone marrow incorporated BrdU into nuclear DNA over a short period and that rapid clearance of the BrdU minimized recirculation and reuse of BrdU (12, 24) , we calculated that the transit time of monocytes through the bone marrow in normal rabbits was 38.1 Ϯ 3.1 h. This is shorter than in humans (ϳ48.2 h) but longer than in rats (ϳ32 h) and mice (28.1 h) (37, 39, 41) . Comparison of the present values for monocyte transit to the previously reported transit time of PMN through the marrow measured using the same technique showed that PMN transit is significantly longer (95.6 Ϯ 3.6 h vs. 38.1 Ϯ 3.1 h) (33) . The present results also show that the introduction of a focal pneumonia significantly shortened the transit time of monocytes through the marrow (Table 1) . Interestingly, even the instillation of the vehicle into the lung also reduced the transit time of monocytes through the marrow, suggesting that just a mild inflammatory insult in the alveolar space (32) results in a monocytic response from the marrow.
Studies from several laboratories including our own have shown that alveolar macrophages are a potent source of inflammatory mediators (2, 16, 32, 35) , and we have shown that several of these mediators have the ability to stimulate the bone marrow (18, 28, 31, 36) . The hematopoietic growth factors, GM-CSF and M-CSF, IL-6, and the ␤-chemokines are thought to be important mediators for the production and mobilization of monocytes from the bone marrow (22, 25). Terashima and colleagues (30) showed an increase in circulating IL-6 and G-CSF in subjects with communityacquired pneumonia, suggesting that these two cytokines contribute to the bone marrow response to bacterial pneumonia. Interleukin-6 is considered an important multifunctional cytokine involved in the regulation of a variety of cellular responses, including hematopoiesis. It is a permissive factor for monocytic colony formation by human hematopoietic progenitor cells (11) . These workers showed that antibody against IL-6 almost completely inhibited the growth of monocytic colonies without decreasing the number of granulocytic colonies. The importance of IL-6 in monocytopoiesis was further demonstrated in serum-deprived bone marrow cultures where the addition of exogenous IL-6 to cultures stimulated with GM-CSF resulted in increased numbers of monocytic colonies. We suspect that IL-6 combined with the colony stimulating factors released from the inflammatory site in the lung is critically important in the production and release of monocytes from the marrow during acute lung inflammation.
The recruitment of leukocyte into a site of acute lung inflammation is characterized by an early recruitment of PMN (1-2 h), followed by a delayed accumulation of monocytes (6, 8, 10, 42) . Monocytes are recruited into lung tissues from the circulation most likely from the large marginating pool of monocytes (6, 17, 21) in the lung. Our data indicate a rapid release of monocytes from the marrow with pneumonia (Fig. 5) that occurs before the PMN are released (33) . Because the migration of monocytes into the lung is delayed compared with PMN, we speculate that these new monocytes enter the marginating pool of cells where they mature before their migration into sites of inflammation.
In summary, we have developed a nonradioisotopic method to measure monocytes behavior in vivo. This method allows the release of monocytes from the marrow to be quantified and their T 1/2 in the circulation pool to be estimated. This novel technique will allow the phenotypic and functional characterization of monocytes that are newly released from the marrow to be compared with fully mature monocytes as they participate in the inflammatory response.
